Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging.

Thompson RB, Chow K, Pagano JJ, Sekowski V, Michelakis ED, Tymchak W, Haykowsky MJ, Ezekowitz JA, Oudit GY, Dyck JRB, Kaul P, Savu A, Paterson DI.

J Cardiovasc Magn Reson. 2019 Sep 12;21(1):58. doi: 10.1186/s12968-019-0567-y.

2.

Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction.

Wang W, Zhang L, Battiprolu PK, Fukushima A, Nguyen K, Milner K, Gupta A, Altamimi T, Byrne N, Mori J, Alrob OA, Wagg C, Fillmore N, Wang SH, Liu DM, Fu A, Lu JY, Chaves M, Motani A, Ussher JR, Reagan JD, Dyck JRB, Lopaschuk GD.

JACC Basic Transl Sci. 2019 Jun 24;4(3):385-400. doi: 10.1016/j.jacbts.2019.02.003. eCollection 2019 Jun.

3.

Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure.

Uddin GM, Zhang L, Shah S, Fukushima A, Wagg CS, Gopal K, Al Batran R, Pherwani S, Ho KL, Boisvenue J, Karwi QG, Altamimi T, Wishart DS, Dyck JRB, Ussher JR, Oudit GY, Lopaschuk GD.

Cardiovasc Diabetol. 2019 Jul 5;18(1):86. doi: 10.1186/s12933-019-0892-3.

4.

Characterisation of the Selective Reduced Uteroplacental Perfusion (sRUPP) Model of Preeclampsia.

Morton JS, Levasseur J, Ganguly E, Quon A, Kirschenman R, Dyck JRB, Fraser GM, Davidge ST.

Sci Rep. 2019 Jul 2;9(1):9565. doi: 10.1038/s41598-019-45959-6.

5.

External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction.

Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J, Paterson I, McAlister FA, Ezekowitz JA.

Circulation. 2019 May 14;139(20):2377-2379. doi: 10.1161/CIRCULATIONAHA.118.038594. No abstract available.

PMID:
31082301
6.

Host-Microbe Interplay in the Cardiometabolic Benefits of Dietary Polyphenols.

Anhê FF, Choi BSY, Dyck JRB, Schertzer JD, Marette A.

Trends Endocrinol Metab. 2019 Jun;30(6):384-395. doi: 10.1016/j.tem.2019.04.002. Epub 2019 May 7. Review.

PMID:
31076221
7.

The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review.

Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA.

Int J Mol Sci. 2019 Feb 19;20(4). pii: E904. doi: 10.3390/ijms20040904. Review.

8.

Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.

Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, Leone T, Dyck JRB, Ussher JR, Muoio DM, Kelly DP, Lopaschuk GD.

Cardiovasc Res. 2019 Sep 1;115(11):1606-1616. doi: 10.1093/cvr/cvz045.

PMID:
30778524
9.

Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites.

Matsumura N, Takahara S, Maayah ZH, Parajuli N, Byrne NJ, Shoieb SM, Soltys CM, Beker DL, Masson G, El-Kadi AOS, Dyck JRB.

J Mol Cell Cardiol. 2018 Dec;125:162-173. doi: 10.1016/j.yjmcc.2018.10.023. Epub 2018 Oct 28.

PMID:
30381233
10.

Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction.

Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Lopaschuk GD.

Mol Med. 2018 Mar 15;24(1):3. doi: 10.1186/s10020-018-0005-x.

11.

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.

Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PWM, Verma S, Dyck JRB.

JACC Basic Transl Sci. 2017 Aug 4;2(4):347-354. doi: 10.1016/j.jacbts.2017.07.003. eCollection 2017 Aug. Review.

12.

Atglistatin ameliorates functional decline in heart failure via adipocyte-specific inhibition of adipose triglyceride lipase.

Parajuli N, Takahara S, Matsumura N, Kim TT, Ferdaoussi M, Migglautsch AK, Zechner R, Breinbauer R, Kershaw EE, Dyck JRB.

Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H879-H884. doi: 10.1152/ajpheart.00308.2018. Epub 2018 Jun 22.

13.

Insulin decreases expression of the proinflammatory receptor proteinase-activated receptor-2 on human airway epithelial cells.

Gandhi VD, Shrestha Palikhe N, Hamza SM, Dyck JRB, Buteau J, Vliagoftis H.

J Allergy Clin Immunol. 2018 Sep;142(3):1003-1006.e8. doi: 10.1016/j.jaci.2018.04.040. Epub 2018 Jun 8. No abstract available.

PMID:
29890235
14.

Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice.

Kim TT, Parajuli N, Sung MM, Bairwa SC, Levasseur J, Soltys CM, Wishart DS, Madsen K, Schertzer JD, Dyck JRB.

Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E511-E519. doi: 10.1152/ajpendo.00471.2017. Epub 2018 Jun 5.

15.

Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.

Matsumura N, Zordoky BN, Robertson IM, Hamza SM, Parajuli N, Soltys CM, Beker DL, Grant MK, Razzoli M, Bartolomucci A, Dyck JRB.

Cardiovasc Res. 2018 Aug 1;114(10):1350-1359. doi: 10.1093/cvr/cvy064.

16.

2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy.

Maayah ZH, Levasseur J, Siva Piragasam R, Abdelhamid G, Dyck JRB, Fahlman RP, Siraki AG, El-Kadi AOS.

Sci Rep. 2018 Feb 9;8(1):2780. doi: 10.1038/s41598-018-20613-9.

17.

Cardiac adaptations to obesity, diabetes and insulin resistance.

Glatz JFC, Dyck JRB, Des Rosiers C.

Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt B):1905-1907. doi: 10.1016/j.bbadis.2018.01.024. Epub 2018 Jan 31. No abstract available.

18.

Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy.

Das SK, Zhabyeyev P, Basu R, Patel VB, Dyck JRB, Kassiri Z, Oudit GY.

Biosci Rep. 2018 Jan 10;38(1). pii: BSR20171302. doi: 10.1042/BSR20171302. Print 2018 Feb 28.

19.

Negative pressure ventilation decreases inflammation and lung edema during normothermic ex-vivo lung perfusion.

Aboelnazar NS, Himmat S, Hatami S, White CW, Burhani MS, Dromparis P, Matsumura N, Tian G, Dyck JRB, Mengel M, Freed DH, Nagendran J.

J Heart Lung Transplant. 2018 Apr;37(4):520-530. doi: 10.1016/j.healun.2017.09.007. Epub 2017 Sep 14.

PMID:
29103845
20.

Volume and Patterns of Physical Activity Across the Health and Heart Failure Continuum.

Yavari M, Haykowsky MJF, Savu A, Kaul P, Dyck JRB, Haennel RG; Alberta HEART Investigators.

Can J Cardiol. 2017 Nov;33(11):1465-1471. doi: 10.1016/j.cjca.2017.07.005. Epub 2017 Jul 18.

PMID:
28985961
21.

Subclinical Pulmonary Edema Is Associated With Reduced Exercise Capacity in HFpEF and HFrEF.

Thompson RB, Pagano JJ, Chow K, Sekowski V, Paterson I, Ezekowitz J, Anderson T, Dyck JRB, Haykowsky MJ; Alberta HEART investigators.

J Am Coll Cardiol. 2017 Oct 3;70(14):1827-1828. doi: 10.1016/j.jacc.2017.07.787. No abstract available.

22.

Cardiovascular susceptibility to in vivo ischemic myocardial injury in male and female rat offspring exposed to prenatal hypoxia.

Shah A, Matsumura N, Quon A, Morton JS, Dyck JRB, Davidge ST.

Clin Sci (Lond). 2017 Aug 10;131(17):2303-2317. doi: 10.1042/CS20171122. Print 2017 Sep 1.

PMID:
28798077
23.

Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels.

Toma M, Mak GJ, Chen V, Hollander Z, Shannon CP, Lam KKY, Ng RT, Tebbutt SJ, Wilson-McManus JE, Ignaszewski A, Anderson T, Dyck JRB, Howlett J, Ezekowitz J, McManus BM, Oudit GY.

ESC Heart Fail. 2017 Aug;4(3):301-311. doi: 10.1002/ehf2.12136. Epub 2017 Mar 4.

24.

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort.

Ezekowitz JA, McAlister FA, Howlett J, Alemayehu W, Paterson I, Belenkie I, Oudit GY, Kaul P, Dyck JR, Anderson T; Alberta HEART Investigators.

ESC Heart Fail. 2018 Feb;5(1):19-26. doi: 10.1002/ehf2.12200. Epub 2017 Jul 25.

25.

Hearts lacking plasma membrane KATP channels display changes in basal aerobic metabolic substrate preference and AMPK activity.

Youssef N, Campbell S, Barr A, Gandhi M, Hunter B, Dolinsky V, Dyck JRB, Clanachan AS, Light PE.

Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H469-H478. doi: 10.1152/ajpheart.00612.2016. Epub 2017 Jun 30.

26.

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.

Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR.

Ann Oncol. 2017 Aug 1;28(8):1836-1841. doi: 10.1093/annonc/mdx264.

PMID:
28520849
27.

Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure.

Sung MM, Byrne NJ, Robertson IM, Kim TT, Samokhvalov V, Levasseur J, Soltys CL, Fung D, Tyreman N, Denou E, Jones KE, Seubert JM, Schertzer JD, Dyck JR.

Am J Physiol Heart Circ Physiol. 2017 Apr 1;312(4):H842-H853. doi: 10.1152/ajpheart.00455.2016. Epub 2017 Feb 3.

28.

Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure.

Sung MM, Byrne NJ, Kim TT, Levasseur J, Masson G, Boisvenue JJ, Febbraio M, Dyck JR.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H552-H560. doi: 10.1152/ajpheart.00626.2016. Epub 2017 Jan 6.

29.

A novel complex I inhibitor protects against hypertension-induced left ventricular hypertrophy.

Matsumura N, Robertson IM, Hamza SM, Soltys CM, Sung MM, Masson G, Beker DL, Dyck JR.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H561-H570. doi: 10.1152/ajpheart.00604.2016. Epub 2017 Jan 6.

30.

The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease.

Ussher JR, Elmariah S, Gerszten RE, Dyck JR.

J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870. doi: 10.1016/j.jacc.2016.09.972. Review.

31.

Improved Glucose Homeostasis in Obese Mice Treated With Resveratrol Is Associated With Alterations in the Gut Microbiome.

Sung MM, Kim TT, Denou E, Soltys CM, Hamza SM, Byrne NJ, Masson G, Park H, Wishart DS, Madsen KL, Schertzer JD, Dyck JR.

Diabetes. 2017 Feb;66(2):418-425. doi: 10.2337/db16-0680. Epub 2016 Nov 30.

32.

Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria.

Alagiakrishnan K, Mah D, Dyck JR, Senthilselvan A, Ezekowitz J.

Int J Cardiol. 2017 Feb 1;228:558-562. doi: 10.1016/j.ijcard.2016.11.193. Epub 2016 Nov 9.

PMID:
27875734
33.

Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats.

Hamza SM, Sung MM, Gao F, Soltys CM, Smith NP, MacDonald PE, Light PE, Dyck JR.

Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):313-322. doi: 10.1016/j.bbagen.2016.11.029. Epub 2016 Nov 19.

PMID:
27871838
34.

The role of post-translational protein modifications on heart and vascular metabolism.

Dyck JR, Glatz JF.

Biochim Biophys Acta. 2016 Dec;1862(12):2197-2198. doi: 10.1016/j.bbadis.2016.09.018. Epub 2016 Sep 28. No abstract available.

35.

Differential Responses of Post-Exercise Recovery of Leg Blood Flow and Oxygen Uptake Kinetics in HFpEF versus HFrEF.

Thompson RB, Pagano JJ, Mathewson KW, Paterson I, Dyck JR, Kitzman DW, Haykowsky MJ.

PLoS One. 2016 Oct 4;11(10):e0163513. doi: 10.1371/journal.pone.0163513. eCollection 2016.

36.

Muscle expression of a malonyl-CoA-insensitive carnitine palmitoyltransferase-1 protects mice against high-fat/high-sucrose diet-induced insulin resistance.

Vavrova E, Lenoir V, Alves-Guerra MC, Denis RG, Castel J, Esnous C, Dyck JR, Luquet S, Metzger D, Bouillaud F, Prip-Buus C.

Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E649-60. doi: 10.1152/ajpendo.00020.2016. Epub 2016 Aug 9.

37.

Inhibition of the Unfolded Protein Response Mechanism Prevents Cardiac Fibrosis.

Groenendyk J, Lee D, Jung J, Dyck JR, Lopaschuk GD, Agellon LB, Michalak M.

PLoS One. 2016 Jul 21;11(7):e0159682. doi: 10.1371/journal.pone.0159682. eCollection 2016.

38.

The role of AMPK in cardiomyocyte health and survival.

Bairwa SC, Parajuli N, Dyck JR.

Biochim Biophys Acta. 2016 Dec;1862(12):2199-2210. doi: 10.1016/j.bbadis.2016.07.001. Epub 2016 Jul 10. Review.

39.

Genetic and Pharmacological Inhibition of Malonyl CoA Decarboxylase Does Not Exacerbate Age-Related Insulin Resistance in Mice.

Ussher JR, Fillmore N, Keung W, Zhang L, Mori J, Sidhu VK, Fukushima A, Gopal K, Lopaschuk DG, Wagg CS, Jaswal JS, Dyck JR, Lopaschuk GD.

Diabetes. 2016 Jul;65(7):1883-91. doi: 10.2337/db15-1145. Epub 2016 May 13.

40.

The role of CD36 in the regulation of myocardial lipid metabolism.

Kim TT, Dyck JR.

Biochim Biophys Acta. 2016 Oct;1861(10):1450-60. doi: 10.1016/j.bbalip.2016.03.018. Epub 2016 Mar 17. Review.

PMID:
26995462
41.

Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression.

Byrne NJ, Levasseur J, Sung MM, Masson G, Boisvenue J, Young ME, Dyck JR.

Cardiovasc Res. 2016 May 15;110(2):249-57. doi: 10.1093/cvr/cvw051. Epub 2016 Mar 10.

42.

Perinatal Resveratrol Supplementation to Spontaneously Hypertensive Rat Dams Mitigates the Development of Hypertension in Adult Offspring.

Care AS, Sung MM, Panahi S, Gragasin FS, Dyck JR, Davidge ST, Bourque SL.

Hypertension. 2016 May;67(5):1038-44. doi: 10.1161/HYPERTENSIONAHA.115.06793. Epub 2016 Feb 29.

PMID:
26928803
43.

Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy.

Das SK, Wang W, Zhabyeyev P, Basu R, McLean B, Fan D, Parajuli N, DesAulniers J, Patel VB, Hajjar RJ, Dyck JR, Kassiri Z, Oudit GY.

Sci Rep. 2015 Dec 7;5:18132. doi: 10.1038/srep18132.

44.

5'-AMP activated protein kinase α2 controls substrate metabolism during post-exercise recovery via regulation of pyruvate dehydrogenase kinase 4.

Fritzen AM, Lundsgaard AM, Jeppesen J, Christiansen ML, Biensø R, Dyck JR, Pilegaard H, Kiens B.

J Physiol. 2015 Nov 1;593(21):4765-80. doi: 10.1113/JP270821.

45.

Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein.

Law J, Salla M, Zare A, Wong Y, Luong L, Volodko N, Svystun O, Flood K, Lim J, Sung M, Dyck JR, Tan CT, Su YC, Yu VC, Mackey J, Baksh S.

J Biol Chem. 2015 Oct 2;290(40):24100-18. doi: 10.1074/jbc.M115.648345. Epub 2015 Aug 12.

46.

Therapeutic potential of resveratrol in heart failure.

Sung MM, Dyck JR.

Ann N Y Acad Sci. 2015 Aug;1348(1):32-45. doi: 10.1111/nyas.12839. Epub 2015 Jul 23. Review.

PMID:
26205211
47.

Skeletal muscle ACC2 S212 phosphorylation is not required for the control of fatty acid oxidation during exercise.

O'Neill HM, Lally JS, Galic S, Pulinilkunnil T, Ford RJ, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR.

Physiol Rep. 2015 Jul;3(7). pii: e12444. doi: 10.14814/phy2.12444.

48.

Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload.

Das SK, DesAulniers J, Dyck JR, Kassiri Z, Oudit GY.

Liver Int. 2016 Feb;36(2):246-57. doi: 10.1111/liv.12893. Epub 2015 Jul 3.

PMID:
26077449
49.

AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.

Sung MM, Zordoky BN, Bujak AL, Lally JS, Fung D, Young ME, Horman S, Miller EJ, Light PE, Kemp BE, Steinberg GR, Dyck JR.

Cardiovasc Res. 2015 Jul 15;107(2):235-45. doi: 10.1093/cvr/cvv166. Epub 2015 May 28.

50.

Metabolomic fingerprint of heart failure with preserved ejection fraction.

Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, Bouatra S, Anderson T, Oudit GY, Wishart DS, Dyck JR; Alberta HEART.

PLoS One. 2015 May 26;10(5):e0124844. doi: 10.1371/journal.pone.0124844. eCollection 2015.

Supplemental Content

Support Center